Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results.
Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular features of two wellknown drugs, ie, rimonabant and...
| Autores: | , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2014 |
| País: | España |
| Recursos: | Instituto de Salud Carlos III (ISCIII) |
| Repositorio: | Repisalud |
| Idioma: | inglés |
| OAI Identifier: | oai:repisalud.isciii.es:20.500.12105/17058 |
| Acesso em linha: | http://hdl.handle.net/20.500.12105/17058 |
| Access Level: | acceso abierto |
| Palavra-chave: | Fentanyl Rimonabant Cannabinoid Opioid Behavioral assays Autopsia Cannabinoides Opioides moduladores de los receptores de cannabinoides Encéfalo Interacciones farmacológicas Cannabinoids Narcotics Autopsy Brain Drug Interactions Cannabinoid Receptor Modulators |
| Resumo: | Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular features of two wellknown drugs, ie, rimonabant and fentanyl. The new compounds have been tested for their affinity and functionality regarding CB1 and CB2 cannabinoid and μ opioid receptors. In [(35)S]-GTPγS (guanosine 5'-O-[gamma-thio]triphosphate) binding assays from the post-mortem human frontal cortex, they proved to be CB1 cannabinoid antagonists and μ opioid antagonists. Interestingly, in vivo, the new compounds exhibited a significant dual antagonist action on the endocannabinoid and opioid systems. |
|---|